Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer
Authors
Keywords
Breast cancer, Cancer stem cells, Epidermal growth factor receptor, Epithelial-to-mesenchymal transition, ADAM metalloprotease
Journal
Molecular Cancer
Volume 16, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-02-02
DOI
10.1186/s12943-017-0599-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- ADAM Proteases and Gastrointestinal Function
- (2016) Jennifer C. Jones et al. Annual Review of Physiology
- The ADAMs family of proteases as targets for the treatment of cancer
- (2016) Maeve Mullooly et al. CANCER BIOLOGY & THERAPY
- ADAM12-L is a direct target of the miR-29 and miR-200 families in breast cancer
- (2015) Sara Duhachek-Muggy et al. BMC CANCER
- Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer
- (2015) Giovanni Ciriello et al. CELL
- Interleukin-6: Biology, signaling and strategies of blockade
- (2015) Fred Schaper et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Identifying and targeting tumor-initiating cells in the treatment of breast cancer
- (2015) W. Wei et al. ENDOCRINE-RELATED CANCER
- Tumor Suppressor NF2 Blocks Cellular Migration by Inhibiting Ectodomain Cleavage of CD44
- (2015) M. Hartmann et al. MOLECULAR CANCER RESEARCH
- Deletions in the cytoplasmic domain of iRhom1 and iRhom2 promote shedding of the TNF receptor by the protease ADAM17
- (2015) Sathish K. Maney et al. Science Signaling
- Deletions in the cytoplasmic domain of iRhom1 and iRhom2 promote shedding of the TNF receptor by the protease ADAM17
- (2015) Sathish K. Maney et al. Science Signaling
- The Disintegrin and Metalloprotease ADAM12 Is Associated with TGF-β-Induced Epithelial to Mesenchymal Transition
- (2015) Michaël Ruff et al. PLoS One
- Cancer stem cells - important players in tumor therapy resistance
- (2014) Selcuk Colak et al. FEBS Journal
- Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization
- (2014) Renaud Sabatier et al. Molecular Cancer
- Phenotypic Diversity of Breast Cancer-Related Mutations in Metalloproteinase-Disintegrin ADAM12
- (2014) Yue Qi et al. PLoS One
- STAT3 Signaling Is Activated Preferentially in Tumor-Initiating Cells in Claudin-Low Models of Human Breast Cancer
- (2014) Wei Wei et al. STEM CELLS
- Targeting Cancer Stem Cell Plasticity Through Modulation of Epidermal Growth Factor and Insulin-Like Growth Factor Receptor Signaling in Head and Neck Squamous Cell Cancer
- (2014) Hui Sun Leong et al. Stem Cells Translational Medicine
- Causal analysis approaches in Ingenuity Pathway Analysis
- (2013) Andreas Krämer et al. BIOINFORMATICS
- Metalloproteinase-disintegrin ADAM12 is associated with a breast tumor-initiating cell phenotype
- (2013) Hui Li et al. BREAST CANCER RESEARCH AND TREATMENT
- Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes
- (2013) Aleix Prat et al. BREAST CANCER RESEARCH AND TREATMENT
- Activation of MAPK Pathways due to DUSP4 Loss Promotes Cancer Stem Cell-like Phenotypes in Basal-like Breast Cancer
- (2013) J. M. Balko et al. CANCER RESEARCH
- Tackling the Diversity of Triple-Negative Breast Cancer
- (2013) N. C. Turner et al. CLINICAL CANCER RESEARCH
- Cancer stem-like cell properties are regulated by EGFR/AKT/β-catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma
- (2013) Lei Ma et al. FEBS Journal
- Notch increases the shedding of HB-EGF by ADAM12 to potentiate invadopodia formation in hypoxia
- (2013) Begoña Díaz et al. JOURNAL OF CELL BIOLOGY
- Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer
- (2013) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes
- (2013) Brian D Lehmann et al. JOURNAL OF PATHOLOGY
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- An essential role of metalloprotease-disintegrin ADAM12 in triple-negative breast cancer
- (2012) Hui Li et al. BREAST CANCER RESEARCH AND TREATMENT
- Role of epidermal growth factor receptor in breast cancer
- (2012) Hiroko Masuda et al. BREAST CANCER RESEARCH AND TREATMENT
- Cancer Stem Cells: Current Status and Evolving Complexities
- (2012) Jane E. Visvader et al. Cell Stem Cell
- TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
- (2012) Lisa A. Carey et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- EGFR Kinase Promotes Acquisition of Stem Cell-Like Properties: A Potential Therapeutic Target in Head and Neck Squamous Cell Carcinoma Stem Cells
- (2012) Eric L. Abhold et al. PLoS One
- Epithelial-Mesenchymal Transition: General Principles and Pathological Relevance with Special Emphasis on the Role of Matrix Metalloproteinases
- (2012) P. Nistico et al. Cold Spring Harbor Perspectives in Biology
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse
- (2011) J. Chuck Harrell et al. BREAST CANCER RESEARCH AND TREATMENT
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Two Phases of Mitogenic Signaling Unveil Roles for p53 and EGR1 in Elimination of Inconsistent Growth Signals
- (2011) Yaara Zwang et al. MOLECULAR CELL
- Stem cell property epithelial-to-mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in KRAS wild-type tumor cells
- (2010) Cristina Oliveras-Ferraros et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
- (2010) A Singh et al. ONCOGENE
- Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
- (2009) B. Corkery et al. ANNALS OF ONCOLOGY
- An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients
- (2009) Balazs Györffy et al. BREAST CANCER RESEARCH AND TREATMENT
- Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines
- (2009) Antoinette Hollestelle et al. BREAST CANCER RESEARCH AND TREATMENT
- Metalloprotease ADAM10 Is Required for Notch1 Site 2 Cleavage
- (2009) Geert van Tetering et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- EGFR ligands and their signaling scissors, ADAMs, as new molecular targets for anticancer treatments
- (2009) Hiromi Kataoka JOURNAL OF DERMATOLOGICAL SCIENCE
- ELDA: Extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays
- (2009) Yifang Hu et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
- (2009) C. J. Creighton et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The ADAM metalloproteinases
- (2008) D EDWARDS et al. MOLECULAR ASPECTS OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started